AstraZeneca PLC/ GB0009895292 /
2024-04-17 5:35:30 PM | Chg. +13.00 | Volume | Bid5:35:30 PM | Ask5:35:30 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
10,903.00GBX | +0.12% | 218,145 Turnover(GBP): 23.7 mill. |
-Bid Size: - | -Ask Size: - | 167.69 bill.GBP | - | - |
GlobeNewswire
04-01
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...
GlobeNewswire
03-28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
GlobeNewswire
03-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Phar...
GlobeNewswire
02-26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
02-05
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, an...
GlobeNewswire
02-02
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patie...
GlobeNewswire
01-16
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Bioph...
GlobeNewswire
01-08
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Bioph...